News

First Patient Receives Novel Heavy-Chain-Only Antibody Treatment in New Phase 1/2a Trial

KisoJi Biotechnology Raises $41 Million to Advance Lead Program Into the Clinic and Deploy AI Tools Into Key Pipeline Indications

Cancer Research UK and KisoJi Biotechnology Collaborate to Advance the First Naked Antibody against TROP2 Into the Clinic